Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease | Zendy

Pinky D. Gaba | Zendy; Connie A. Haley | Zendy; Marie R. Griffin | Zendy; Ed Mitchel | Zendy; Jon Warkentin | Zendy; Erin Holt | Zendy; Pam Baggett | Zendy; Timothy R. Sterling | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Increasing Outpatient Fluoroquinolone Exposure Before Tuberculosis Diagnosis and Impact on Culture-Negative Disease

Author(s) -

Pinky D. Gaba,

Connie A. Haley,

Marie R. Griffin,

Ed Mitchel,

Jon Warkentin,

Erin Holt,

Pam Baggett,

Timothy R. Sterling

Publication year - 2007

Publication title -

archives of internal medicine

Language(s) - English

Resource type - Journals

eISSN - 1538-3679

pISSN - 0003-9926

DOI - 10.1001/archinte.167.21.2317

Subject(s) - medicine , tuberculosis , mycobacterium tuberculosis , odds ratio , tuberculosis diagnosis , immunology , pediatrics , pathology

Fluoroquinolones are widely used to treat routine bacterial infections, but they are also potential first-line antituberculosis agents. Empirical fluoroquinolone therapy can delay the diagnosis of tuberculosis and cause resistance in Mycobacterium tuberculosis. Rates of fluoroquinolone exposure before tuberculosis diagnosis and the impact of fluoroquinolones on culture-negative tuberculosis have not been previously reported.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research